1. Home
  2. MRK vs SCLXW Comparison

MRK vs SCLXW Comparison

Compare MRK & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Merck & Company Inc. (new)

MRK

Merck & Company Inc. (new)

HOLD

Current Price

$123.25

Market Cap

268.7B

Sector

Health Care

ML Signal

HOLD

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

HOLD

Current Price

$0.10

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRK
SCLXW
Founded
2000
N/A
Country
United States
United States
Employees
N/A
30
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
268.7B
N/A
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
MRK
SCLXW
Price
$123.25
$0.10
Analyst Decision
Buy
Analyst Count
16
0
Target Price
$124.38
N/A
AVG Volume (30 Days)
6.5M
3.2K
Earning Date
04-30-2026
03-07-2025
Dividend Yield
2.85%
N/A
EPS Growth
8.01
N/A
EPS
7.28
N/A
Revenue
$65,011,000,000.00
$55,152,000.00
Revenue This Year
$3.73
N/A
Revenue Next Year
$5.42
N/A
P/E Ratio
$16.33
N/A
Revenue Growth
1.31
22.02
52 Week Low
$75.40
$0.04
52 Week High
$125.14
$0.64

Technical Indicators

Market Signals
Indicator
MRK
SCLXW
Relative Strength Index (RSI) 63.88 40.81
Support Level $113.27 $0.09
Resistance Level $125.14 $0.12
Average True Range (ATR) 2.67 0.02
MACD 0.49 -0.00
Stochastic Oscillator 96.55 22.12

Price Performance

Historical Comparison
MRK
SCLXW

About MRK Merck & Company Inc. (new)

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: